STOCK TITAN

So-Young (Nasdaq: SY) narrows 2025 loss and guides strong Q1 2026 growth

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

So-Young International Inc. reported narrower losses on growing aesthetic services for Q4 and full-year 2025 but remains unprofitable. Fourth quarter revenues reached RMB460.7 million (US$65.9 million), up 24.8% from RMB369.2 million a year earlier, mainly driven by expansion of branded aesthetic centers.

Q4 net loss attributable to the company shrank sharply to RMB108.8 million (US$15.6 million) from RMB607.6 million, while non-GAAP net loss widened to RMB93.4 million (US$13.2 million) from RMB53.2 million. For 2025, revenues were RMB1,523.4 million (US$217.8 million), a 3.9% increase, and net loss improved to RMB242.3 million (US$34.6 million) from RMB589.5 million.

Full-year non-GAAP net loss expanded to RMB217.1 million (US$31.0 million) from RMB4.7 million as the company added new non-GAAP adjustment items. Cash, cash equivalents, restricted cash, term deposits and short-term investments totaled RMB936.4 million (US$133.9 million) as of December 31, 2025. The share repurchase program of up to US$25 million has been extended through March 31, 2027, with about 4.8 million ADSs repurchased in 2024 and 2025. For Q1 2026, So-Young expects aesthetic treatment services revenues between RMB268.0 million and RMB278.0 million, implying 171.2% to 181.3% growth over the prior year.

Positive

  • None.

Negative

  • None.

Insights

Losses narrow and aesthetic centers surge, but core earnings remain weak.

So-Young delivered strong Q4 growth, with revenues up 24.8% to RMB460.7 million, largely from branded aesthetic centers. Operating efficiency improved as Q4 net loss fell to RMB108.8 million from RMB607.6 million, helped by a much lower impairment charge.

However, full-year fundamentals are mixed. Revenue for 2025 grew only 3.9% to RMB1,523.4 million, while non-GAAP net loss widened sharply to RMB217.1 million from RMB4.7 million, reflecting new adjustments and continuing investment in self-operated centers. Cash and investments of RMB936.4 million provide a buffer but declined from RMB1,253.2 million as capital was deployed into centers.

Management guided aesthetic treatment services revenues of RMB268.0–278.0 million for Q1 2026, implying triple-digit year-on-year growth, signaling confidence in the offline expansion strategy. The extension of the up-to-US$25 million share repurchase program through March 31, 2027 suggests ongoing capital return, but the investment case still hinges on whether high growth in center revenues can translate into sustainable profitability in coming reporting periods.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2026

 

 

 

Commission File Number: 001-38878

 

 

 

So-Young International Inc.

 

2/F, East Tower, Poly Plaza

No. 66 Xiangbin Road

Chaoyang District, Beijing, 100012

People’s Republic of China

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x         Form 40-F ¨

 

 

 

 

 

 

 

Exhibit Index

 

Exhibit 99.1—Press Release

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  So-Young International Inc.
       
  By   :

/s/ Xing Jin

  Name : Xing Jin
  Title : Chief Executive Officer

 

Date: March 25, 2026

 

3

 

 

Exhibit 99.1

 

 

So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

 

BEIJING, China, Mar. 25, 2026 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.

 

Fourth Quarter 2025 Financial Highlights

 

·Total revenues were RMB460.7 million (US$65.9 million1), compared with RMB369.2 million in the corresponding period of 2024. The aesthetic treatment services revenues were RMB248.1 million (US$35.5 million), compared with RMB81.3 million in the corresponding period of 2024, exceeding the high end of guidance.

 

·Net loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million), compared with net loss attributable to So-Young International Inc. of RMB607.6 million in the same period of 2024.

 

·Non-GAAP net loss attributable to So-Young International Inc.2 was RMB93.4 million (US$13.2 million), compared with non-GAAP net loss attributable to So-Young International Inc. of RMB53.2 million in the same period of 2024.

 

Fourth Quarter 2025 Operational Highlights

 

·The number of verified treatment visits to the branded aesthetic centers for the quarter reached over 125,000, compared with approximately 45,000 in the same period of 2024. The number of verified aesthetic treatments performed surpassed 289,400, compared with approximately 107,900 in the same period of 2024.

 

·The number of active users, defined as those who visited branded aesthetic centers at least once during the 12-month period ended on December 31, 2025, exceeded 171,000, compared with approximately 52,700 users during the corresponding period in 2024.

 

·The number of core members grew by over 14,500 during the quarter, representing an approximately 39% sequential increase. Both the revenue contribution from core members to aesthetic treatment services and their quarterly repurchase rate exceeded 80%.

 

·As of December 31, 2025, So-Young had 49 fully operational branded aesthetic centers (48 directly-operated, 1 franchised) across fifteen major cities: Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, Chongqing, Ningbo, Changsha, Tianjin, Xi’an, Suzhou, Hefei and Kunming. Among them, 25 centers achieved profitability* in the fourth quarter. In addition, 39 centers generated positive quarterly operating cash flow* in the fourth quarter. The following table shows the revenues generated by So-Young aesthetic centers, categorized by their phase of development:

 

 

1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.9931 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 31, 2025.

 

2 Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

 

1

 

 

Phase** (Operating duration)  Number of Centers   Revenue (RMB)   Average Revenue per Center (RMB)   Average Center Age (Month) 
Ramp-up (0-3 months)   13    16,598,000    1,277,000    1.2 
Growth (4-12 months)   19    88,955,000    4,682,000    7.1 
Maturity (over 12 months)   17    142,523,000    8,384,000    17.8 

 

* Center-level profitability measures whether an individual aesthetic center achieved positive profit in a given period. It is calculated by deducting consumable materials costs, personnel costs, center rental expenses, center depreciation expenses, and other center-level operating costs from the company’s self-operated store revenues, before allocation of any back-office or mid-office expenses. Quarterly operating cash flow refers to total cash collected from orders less center-level operating payments in a given period, and excluding operating expense payments made by back-office or mid-office departments during the same period. Center-level profitability and quarterly operating cash flow are metrics derived from the Company's internal management accounts, which have not been audited.

 

** For the purposes of this table, “Phase” refers to the length of time since commencement of actual operations rather than the legal establishment or registration date of a branded aesthetic center. In cases where a center has been relocated, merged, or its team and customer base transferred to another location, the operating duration of the branded aesthetic center is calculated from the commencement date of the predecessor center’s operations. Periods during which a center is temporarily closed and not conducting external operations (e.g., due to renovation or other suspensions of business) are excluded from the calculation of operating duration. Branded aesthetic centers that have been converted to other uses or are no longer within the reporting scope are excluded from the statistics.

 

Fiscal Year 2025 Financial Highlights

 

·Total revenues were RMB1,523.4 million (US$217.8 million) in fiscal year 2025, compared with RMB1,466.7 million in the prior year.

 

·Net loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million) in fiscal year 2025, compared with a net loss attributable to So-Young International Inc. of RMB589.5 million in the prior year.

 

·Non-GAAP net loss attributable to So-Young International Inc. was RMB217.1 million (US$31.0 million) in fiscal year 2025, compared with a non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 million in the prior year.

 

Extension of Share Repurchase Program

 

The share repurchase program, initially approved on March 18, 2024, authorizing the repurchase of up to US$25 million in ADSs or ordinary shares, has been extended for an additional 12-month period through March 31, 2027. In 2024 and 2025, the Company repurchased approximately 4.8 million ADSs. All other terms remain unchanged.

 

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “In the fourth quarter, our aesthetic center business maintained its strong momentum, solidifying its role as a core growth engine for the Group. We have retained our position as China’s leading light medical aesthetics chain by scale, which serves as a clear validation of our business model’s strength and sustainability. Looking ahead, we will pursue steady store expansion while prioritizing operational excellence and industry-leading standards. Through strategic alliances with upstream manufacturers and a commitment to genuine product traceability, we are building competitive advantages rooted in both unit economics and trust. We are confident that this disciplined approach will drive sustainable value for our shareholders.”

 

Fourth Quarter 2025 Financial Results

 

Revenues

 

Total revenues were RMB460.7 million (US$65.9 million), an increase of 24.8% from RMB369.2 million in the same period of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

 

·Aesthetic treatment services revenues were RMB248.1 million (US$35.5 million), an increase of 205.3% from RMB81.3 million in the same period of 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

2

 

 

·Information and reservation services3 revenues were RMB125.7 million (US$18.0 million), a decrease of 26.8% from RMB171.6 million in the same period of 2024. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.

 

·Sales of medical products and maintenance services revenues were RMB69.3 million (US$9.9 million), a decrease of 19.9% from RMB86.4 million in the same period of 2024, primarily due to a decrease in the order volume for medical equipment.

 

·Other services revenues were RMB17.7 million (US$2.5 million), a decrease of 40.7% from RMB29.9 million in the same period of 2024, primarily due to a decrease in revenues from So-Young Prime.

 

Cost of Revenues

 

Cost of revenues was RMB255.9 million (US$36.6 million), an increase of 67.2% from RMB153.1 million in the fourth quarter of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

 

·Cost of aesthetic treatment services was RMB189.0 million (US$27.0 million), an increase of 189.9% from RMB65.2 million in the fourth quarter of 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

·Cost of information and reservation services4 was RMB10.1 million (US$1.4 million), a decrease of 50.6% from RMB20.4 million in the fourth quarter of 2024. The decrease was in line with the decrease in revenue generated from information and reservation services.

 

·Cost of medical products sold and maintenance services was RMB41.6 million (US$5.9 million), a decrease of 4.0% from RMB43.3 million in the fourth quarter of 2024. The decrease was primarily due to a decrease in costs associated with the sales of medical equipment.

 

·Cost of other services was RMB15.3 million (US$2.2 million), a decrease of 36.7% from RMB24.1 million in the fourth quarter of 2024. The decrease was primarily due to a decrease in costs associated with So-Young Prime.

 

Operating Expenses

 

Total operating expenses were RMB327.7 million (US$46.9 million), a decrease of 59.8% from RMB815.2 million in the fourth quarter of 2024.

 

·Sales and marketing expenses were RMB168.7 million (US$24.1 million), an increase of 25.8% from RMB134.0 million in the fourth quarter of 2024. The increase was primarily attributable to an increase in expenses associated with branding and user acquisition activities for the branded aesthetic centers.

 

·General and administrative expenses were RMB101.9 million (US$14.6 million), an increase of 3.5% from RMB98.4 million in the fourth quarter of 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

 

3 Since the second quarter of 2025, in light of the better monitoring business development of branded aesthetic centers, the previous line item information, reservation services and others was separated into two line items, which are information and reservation services and other services.

 

The revenue generated from information and reservation services and other services for the fourth quarter of 2024 have also been retrospectively updated. The amount reclassified from previous line item information, reservation services and others to information and reservation services is RMB171.6 million for the fourth quarter of 2024.

 

4 Since the second quarter of 2025, the previous line item cost of information, reservation services and others was separated into two line items, which are cost of information and reservation services and cost of other services. Cost of information and reservation services primarily consists of expenditures relating to operation of platform business, and the remaining cost of information, reservation services and others is reclassified into cost of other services. The cost of information and reservation services and cost of other services for the fourth quarter of 2024 have also been retrospectively reclassified.

 

3

 

 

·Research and development expenses were RMB37.4 million (US$5.4 million), a decrease of 12.4% from RMB42.8 million in the fourth quarter of 2024. The decrease was primarily attributable to improvements in staff efficiency.

 

·Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 million) in this quarter, representing the amount by which the carrying amount of certain asset exceeds their fair value, based on an annual long-lived assets impairment assessment. Impairment of goodwill was RMB540.0 million in the fourth quarter of 2024.

 

Income Tax Benefits/(Expenses)

 

Income tax benefits were RMB0.6 million (US$0.1 million), compared with income tax expenses of RMB2.1 million in the same period of 2024.

 

Net Loss Attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million), compared with a net loss attributable to So-Young International Inc. of RMB607.6 million in the fourth quarter of 2024.

 

Non-GAAP Net Loss Attributable to So-Young International Inc.

 

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB93.4 million (US$13.2 million), compared with RMB53.2 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2024.

 

Basic and Diluted Loss per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB1.08 (US$0.15) and RMB1.08 (US$0.15), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.92 and RMB5.92, respectively, in the same period of 2024.

 

Fiscal Year 2025 Financial Results

 

Revenues

 

Total revenues were RMB1,523.4 million (US$217.8 million), an increase of 3.9% from RMB1,466.7 million in fiscal year 2024.

 

Aesthetic treatment services revenues were RMB674.9 million (US$96.5 million), an increase of 298.7% from RMB169.3 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

Information and reservation services revenues were RMB499.7 million (US$71.5 million), a decrease of 32.2% from RMB736.6 million in fiscal year 2024. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young’s platform.

 

Sales of medical products and maintenance services revenues were RMB267.8 million (US$38.3 million), a decrease of 27.2% from RMB368.0 million in fiscal year 2024, primarily due to a decrease in sales of medical equipment.

 

Other services revenues were RMB81.0 million (US$11.6 million), a decrease of 58.0% from RMB192.8 million in the same period of 2024, primarily due to a decrease in revenues from So-Young Prime.

 

4

 

 

Cost of Revenues

 

Cost of revenues was RMB795.7 million (US$113.8 million), an increase of 40.2% from RMB567.6 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

·Cost of aesthetic treatment services was RMB518.7 million (US$74.2 million), an increase of 294.2% from RMB131.6 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

·Cost of information and reservation services was RMB63.0 million (US$9.0 million), a decrease of 41.1% from RMB107.0 million in fiscal year 2024. The decrease was in line with the decrease in revenue generated from information and reservation services.

 

·Cost of medical products sold and maintenance services was RMB147.1 million (US$21.0 million), a decrease of 19.7% from RMB183.2 million in fiscal year 2024. The decrease was primarily due to a decrease in costs associated with the sales of medical equipment.

 

·Cost of other services was RMB66.9 million (US$9.6 million), a decrease of 54.1% from RMB145.9 million in fiscal year of 2024. The decrease was primarily due to a decrease in costs associated with So-Young Prime.

 

Operating Expenses

 

Total operating expenses were RMB1,013.9 million (US$145.0 million), a decrease of 33.5% from RMB1,523.6 million in fiscal year 2024.

 

Sales and marketing expenses were RMB528.6 million (US$75.6 million), an increase of 6.9% from RMB494.5 million in fiscal year 2024. The increase was primarily attributable to an increase in expenses associated with branding and user acquisition activities for the branded aesthetic centers.

 

General and administrative expenses were RMB328.5 million (US$47.0 million), an increase of 1.4% from RMB324.1 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

 

Research and development expenses were RMB137.0 million (US$19.6 million), a decrease of 17.0% from RMB165.0 million in fiscal year 2024. The decrease was primarily attributable to improvements in staff efficiency.

 

Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 million) in this year, representing the amount by which the carrying amount of certain asset exceeds their fair value, based on an annual long-lived assets impairment assessment. Impairment of goodwill was RMB540.0 million in fiscal year 2024.

 

Income Tax (Expenses)/Benefits

 

Income tax expenses were RMB0.8 million (US$0.1 million), compared with an income tax benefits of RMB0.9 million in fiscal year 2024.

 

Net Loss Attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million), compared with a net loss attributable to So-Young International Inc. of RMB589.5 million in fiscal year 2024.

 

Non-GAAP Net Loss Attributable to So-Young International Inc.

 

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB217.1 million (US$31.0 million), compared with a non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 million in fiscal year 2024.

 

5

 

 

Basic and Diluted Loss per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB2.39 (US$0.34) and RMB2.39 (US$0.34), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.72 and RMB5.72 in fiscal year 2024.

 

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

 

As of December 31, 2025, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB936.4 million (US$133.9 million), compared with RMB1,253.2 million as of December 31, 2024, primarily due to an increase of investment in branded aesthetic centers.

 

Business Outlook

 

For the first quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB268.0 million (US$38.3 million) and RMB278.0 million (US$39.8 million), representing a 171.2% to 181.3% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

 

Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and long-lived assets from income/(loss) from operations, and excluding share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments from net income/(loss) attributable to So-Young International Inc., respectively. Starting from the fourth quarter of 2024, the Company newly included impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments as additional adjustments in its non-GAAP financial measures, which may result in differences from previously disclosed non-GAAP figures.

 

The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company’s core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses, the impairment of goodwill and long-lived assets, impairment of long-term investment and allowance for credit loss from loans to investees are non-cash in nature. Gain/(loss) on disposal of long-term investment and fair value change of long-term investment are non-recurring in nature. And, in substance, both impairment of long-term investment and allowance for credit loss from loans to investees are impairment of investment. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

 

6

 

 

Conference Call Information

 

So-Young’s management will hold an earnings conference call on Wednesday, March 25, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 

International: +1-412-902-4272
Mainland China: 4001-201203
US: +1-888-346-8982
Hong Kong: +852-800-905-945
Passcode: So Young

 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, April 1, 2026. The dial-in details are:

 

International: +1-412-317-0088
US: +1-855-669-9658
Passcode: 5232304

 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

 

About So-Young International Inc.

 

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

 

For more information, please contact:

 

So-Young

 

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

 

Christensen

 

Ms. Charlie Chi

Phone: +86-10-5900-1548

E-mail: sy@christensencomms.com

 

7

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

 

   As of 
   December 31,   December 31,   December 31, 
   2024   2025   2025 
   RMB   RMB   US$ 
Assets            
Current assets:               
Cash and cash equivalents   587,749    418,213    59,804 
Restricted cash and term deposits   66,367    64,683    9,250 
Trade receivables   98,774    51,532    7,369 
Inventories   151,754    233,389    33,374 
Receivables from online payment platforms   24,255    16,296    2,330 
Amounts due from related parties   1,218    774    111 
Term deposits and short-term investments   599,041    453,472    64,846 
Prepayment and other current assets   195,202    246,237    35,211 
Total current assets   1,724,360    1,484,596    212,295 
Non-current assets:               
Long-term investments   280,281    274,753    39,289 
Intangible assets   126,615    144,097    20,606 
Goodwill   684    684    98 
Property and equipment, net   155,352    293,560    41,979 
Deferred tax assets   84,950    69,313    9,912 
Operating lease right-of-use assets   162,764    251,635    35,983 
Other non-current assets   200,152    130,998    18,732 
Total non-current assets   1,010,798    1,165,040    166,599 
Total assets   2,735,158    2,649,636    378,894 
                
Liabilities               
Current liabilities:               
Short-term borrowings   69,771    39,814    5,693 
Taxes payable   61,862    43,461    6,215 
Contract liabilities   76,579    65,948    9,430 
Salary and welfare payables   111,396    130,170    18,614 
Amounts due to related parties   477    618    88 
Accrued expenses and other current liabilities   265,216    427,507    61,134 
Operating lease liabilities-current   44,905    76,536    10,945 
Total current liabilities   630,206    784,054    112,119 
Non-current liabilities:               
Operating lease liabilities-non current   125,200    183,364    26,221 
Deferred tax liabilities   19,758    10,615    1,518 
Other non-current liabilities   1,264    2,783    398 
Total non-current liabilities   146,222    196,762    28,137 
Total liabilities   776,428    980,816    140,256 

 

8

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

(Amounts in thousands, except for share and per share data)

 

Shareholders’ equity:            
Treasury stock   (376,690)   (391,944)   (56,047)
Class A ordinary shares (US$0.0005 par value; 750,000,000 shares authorized as of December 31, 2024 and December 31, 2025; 77,897,969 and 65,659,510 shares issued and outstanding as of December 31, 2024, 79,016,808 and 65,089,482 shares issued and outstanding as of December 31, 2025, respectively)   253    257    37 
Class B ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2024 and December 31, 2025; 12,000,000 shares issued and outstanding as of December 31, 2024 and December 31, 2025)   37    37    5 
Additional paid-in capital   3,069,799    3,059,764    437,540 
Statutory reserves   40,552    46,448    6,642 
Accumulated deficit   (926,390)   (1,174,587)   (167,964)
Accumulated other comprehensive income   31,560    13,340    1,908 
Total So-Young International Inc. shareholders’ equity   1,839,121    1,553,315    222,121 
Non-controlling interests   119,609    115,505    16,517 
Total shareholders’ equity   1,958,730    1,668,820    238,638 
Total liabilities and shareholders’ equity   2,735,158    2,649,636    378,894 

 

9

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December 31, 2024   December 31, 2025   December 31, 2025   December 31, 2024   December 31, 2025   December 31, 2025 
   RMB   RMB   US$   RMB   RMB   US$ 
Revenues:                              
Aesthetic treatment services   81,267    248,076    35,474    169,263    674,903    96,510 
Information and reservation services   171,624    125,675    17,971    736,607    499,685    71,454 
Sales of medical products and maintenance services   86,432    69,257    9,904    367,980    267,839    38,300 
Other services   29,888    17,714    2,533    192,848    80,983    11,580 
Total revenues   369,211    460,722    65,882    1,466,698    1,523,410    217,844 
Cost of revenues:                              
Cost of aesthetic treatment services   (65,208)   (189,017)   (27,029)   (131,580)   (518,749)   (74,180)
Cost of information and reservation services   (20,384)   (10,071)   (1,440)   (106,958)   (62,970)   (9,005)
Cost of medical products sold and maintenance services   (43,325)   (41,595)   (5,948)   (183,164)   (147,110)   (21,036)
Cost of other services   (24,134)   (15,265)   (2,183)   (145,883)   (66,894)   (9,566)
Total cost of revenues   (153,051)   (255,948)   (36,600)   (567,585)   (795,723)   (113,787)
Gross profit   216,160    204,774    29,282    899,113    727,687    104,057 
Operating expenses:                              
Sales and marketing expenses   (134,045)   (168,678)   (24,121)   (494,493)   (528,591)   (75,588)
General and administrative expenses   (98,420)   (101,893)   (14,571)   (324,073)   (328,523)   (46,978)
Research and development expenses   (42,753)   (37,436)   (5,353)   (165,030)   (137,040)   (19,596)
Impairment of goodwill and long-lived assets   (540,009)   (19,710)   (2,818)   (540,009)   (19,710)   (2,818)
Total operating expenses   (815,227)   (327,717)   (46,863)   (1,523,605)   (1,013,864)   (144,980)
Loss from operations   (599,067)   (122,943)   (17,581)   (624,492)   (286,177)   (40,923)
Other income/(expenses):                              
Investment income, net   7,623    773    111    11,020    1,738    249 
Interest income, net   8,237    3,453    494    46,507    23,556    3,368 
Exchange (losses)/gains   (763)   2,929    419    112    5,948    851 
Impairment of long-term investment   (7,350)           (7,350)        
Share of losses of equity method investee   (3,413)   (616)   (88)   (15,015)   (4,076)   (583)
Others, net   (11,103)   1,670    238    1,131    12,902    1,845 
Loss before tax   (605,836)   (114,734)   (16,407)   (588,087)   (246,109)   (35,193)
Income tax (expenses)/benefits   (2,126)   619    89    905    (796)   (114)
Net loss   (607,962)   (114,115)   (16,318)   (587,182)   (246,905)   (35,307)
Net loss/(income) attributable to noncontrolling interests   386    5,266    753    (2,345)   4,604    658 
Net loss attributable to So-Young International Inc.   (607,576)   (108,849)   (15,565)   (589,527)   (242,301)   (34,649)

 

10

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December 31, 2024   December 31, 2025   December 31, 2025   December 31, 2024   December 31, 2025   December 31, 2025 
   RMB   RMB   US$   RMB   RMB   US$ 
Net loss per ordinary share                        
Net loss per ordinary share attributable to ordinary shareholder - basic   (7.70)   (1.40)   (0.20)   (7.43)   (3.11)   (0.44)
Net loss per ordinary share attributable to ordinary shareholder - diluted   (7.70)   (1.40)   (0.20)   (7.43)   (3.11)   (0.44)
Net loss per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares)   (5.92)   (1.08)   (0.15)   (5.72)   (2.39)   (0.34)
Net loss per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares)   (5.92)   (1.08)   (0.15)   (5.72)   (2.39)   (0.34)
Weighted average number of ordinary shares used in computing loss per share, basic*   78,905,617    77,593,230    77,593,230    79,384,454    77,863,698    77,863,698 
Weighted average number of ordinary shares used in computing loss per share, diluted*   78,905,617    77,593,230    77,593,230    79,384,454    77,863,698    77,863,698 
                               
Share-based compensation expenses included in:                              
Cost of revenues   (34)   4    1    (289)   (185)   (26)
Sales and marketing expenses   (239)   30    4    (659)   (835)   (119)
General and administrative expenses   (1,731)   771    110    (29,527)   (7,118)   (1,018)
Research and development expenses   (211)   66    9    (2,180)   (780)   (112)
                               

 

*Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

11

 

 

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Fiscal Year Ended 
   December 31, 2024   December 31, 2025   December 31, 2025   December 31, 2024   December 31, 2025   December 31, 2025 
   RMB   RMB   US$   RMB   RMB   US$ 
GAAP loss from operations   (599,067)   (122,943)   (17,581)   (624,492)   (286,177)   (40,923)
Add back: Share-based compensation expenses   2,215    (871)   (124)   32,655    8,918    1,275 
Add back: Impairment of goodwill and long-lived assets   540,009    19,710    2,818    540,009    19,710    2,818 
Non-GAAP loss from operations   (56,843)   (104,104)   (14,887)   (51,828)   (257,549)   (36,830)
                               
GAAP net loss attributable to So-Young International Inc.   (607,576)   (108,849)   (15,565)   (589,527)   (242,301)   (34,649)
Add back: Share-based compensation expenses   2,215    (871)   (124)   32,655    8,918    1,275 
Add back: Impairment of goodwill and long-lived assets attributable to So-Young International Inc.   540,009    18,782    2,818    540,009    18,782    2,686 
Add back: Impairment of long-term investment attributable to So-Young International Inc.   7,350            7,350         
Add back: Allowance for credit loss from loans to investees attributable to So-Young International Inc.   13,843            13,843         
Reversal: Gain on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc.   (7,791)           (7,791)        
Reversal: Tax effects on non-GAAP adjustments (1)   (1,276)   (2,483)   (355)   (1,276)   (2,483)   (355)
Non-GAAP net loss attributable to So-Young International Inc.   (53,226)   (93,421)   (13,226)   (4,737)   (217,084)   (31,043)

 

 

(1) To adjust the income tax effects of non-GAAP adjustments, which is primarily related to allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment, fair value change of long-term investment and impairment of long-lived assets. Other non-GAAP adjustment items have no tax effect, because full valuation allowances were provided for related deferred tax assets as it is more-likely-than-not they will not be realized.

 

12

 

FAQ

How did So-Young (SY) perform financially in Q4 2025?

So-Young reported Q4 2025 revenues of RMB460.7 million (US$65.9 million), up 24.8% year over year. Net loss attributable to the company narrowed significantly to RMB108.8 million from RMB607.6 million, mainly as large prior-year impairment charges did not repeat.

What were So-Young (SY) full-year 2025 revenues and net loss?

For 2025, So-Young generated revenues of RMB1,523.4 million (US$217.8 million), a 3.9% increase over 2024. Net loss attributable to the company improved to RMB242.3 million (US$34.6 million), compared with a net loss of RMB589.5 million in the prior year.

How did So-Young’s non-GAAP net loss change in 2025?

Non-GAAP net loss attributable to So-Young widened to RMB217.1 million (US$31.0 million) in 2025 from RMB4.7 million in 2024. The company added new adjustment items, including investment-related impairments and fair value changes, affecting comparability to earlier non-GAAP figures.

What guidance did So-Young (SY) provide for Q1 2026 aesthetic services?

For Q1 2026, So-Young expects aesthetic treatment services revenues between RMB268.0 million and RMB278.0 million, or US$38.3–39.8 million. This represents projected growth of 171.2% to 181.3% compared with the same period in 2025, driven by branded aesthetic centers.

What is the status of So-Young’s share repurchase program?

So-Young’s share repurchase program authorizing up to US$25 million in ADSs or ordinary shares has been extended through March 31, 2027. In 2024 and 2025, the company repurchased approximately 4.8 million ADSs under this program, with all other terms unchanged.

How strong is So-Young’s cash and investment position at year-end 2025?

As of December 31, 2025, So-Young held cash and cash equivalents, restricted cash, term deposits and short-term investments totaling RMB936.4 million (US$133.9 million). This compares with RMB1,253.2 million a year earlier, reflecting increased investment in branded aesthetic centers.

Filing Exhibits & Attachments

1 document
So-Young Intl

NASDAQ:SY

View SY Stock Overview

SY Rankings

SY Latest News

SY Latest SEC Filings

SY Stock Data

289.95M
83.10M
Health Information Services
Healthcare
Link
China
Chaoyang